Clinical trial
A Randomized, Double-Blind, Multi-Center, Phase III Trial to Evaluate the Efficacy and Safety of KDF1901 in Patients With Essential Hypertension Inappropriately Controlled on KDF1901-R0 Treatment
NCT07116863 is registered in ClinicalTrials.gov with Kyungdong Pharmaceutical Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-Blind, Multi-Center, Phase III Trial to Evaluate the Efficacy and Safety of KDF1901 in Patients With Essential Hypertension Inappropriately Controlled on KDF1901-R0 Treatment
- Lead sponsor
- Kyungdong Pharmaceutical Co., Ltd.
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- June 21, 2022
- Completion date
- September 13, 2024
- Enrollment
- 286 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.